Shuai Wang1, Xiaohong Han1, Xingsheng Hu1, Xiaoyuan Wang1, Lingdi Zhao1, Le Tang1, Yun Feng1, Di Wu1, Yan Sun1, Yuankai Shi2. 1. Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. 2. Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. Electronic address: syuankai@cicams.ac.cn.
Abstract
BACKGROUND: The use of biomarkers for selecting non-small cell lung cancer (NSCLC) patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is essential. The aim of this study was to explore whether biomarkers detected in plasma were predictive for response to EGFR-TKIs and survival time of NSCLC patients. METHODS: Tumor tissues and paired blood were collected from 134 advanced NSCLC patients treated with EGFR-TKIs. EGFR mutations in both types of specimens, and expression of transforming growth factor-alpha and beta one (TGF-α and TGF-β1) were assessed in NSCLC patients. Concentrations of circulating free DNA were detected in plasma from both NSCLC patients and healthy subjects. The clinical significance of EGFR mutations, levels of cytokines, and circulating free DNA was assessed in advanced NSCLC patients. RESULTS: EGFR mutations were detected in 68 tumor samples and 17 plasma samples of 134 NSCLC patients. The concentrations of circulating free DNA were higher in NSCLC patients than in healthy subjects. Patients with high TGF-β1 level showed shorter overall survival and worse response to EGFR-TKIs than patients with low TGF-β1 level. CONCLUSIONS: Plasma levels of TGF-β1 may be a marker for predicting response to EGFR-TKIs and survival time in NSCLC patients.
BACKGROUND: The use of biomarkers for selecting non-small cell lung cancer (NSCLC) patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is essential. The aim of this study was to explore whether biomarkers detected in plasma were predictive for response to EGFR-TKIs and survival time of NSCLCpatients. METHODS:Tumor tissues and paired blood were collected from 134 advanced NSCLCpatients treated with EGFR-TKIs. EGFR mutations in both types of specimens, and expression of transforming growth factor-alpha and beta one (TGF-α and TGF-β1) were assessed in NSCLCpatients. Concentrations of circulating free DNA were detected in plasma from both NSCLCpatients and healthy subjects. The clinical significance of EGFR mutations, levels of cytokines, and circulating free DNA was assessed in advanced NSCLCpatients. RESULTS:EGFR mutations were detected in 68 tumor samples and 17 plasma samples of 134 NSCLCpatients. The concentrations of circulating free DNA were higher in NSCLCpatients than in healthy subjects. Patients with high TGF-β1 level showed shorter overall survival and worse response to EGFR-TKIs than patients with low TGF-β1 level. CONCLUSIONS: Plasma levels of TGF-β1 may be a marker for predicting response to EGFR-TKIs and survival time in NSCLCpatients.
Authors: Dong Soo Lee; Kyung Ran Park; Seung Joon Kim; Mi Joo Chung; Yun Hee Lee; Ji Hyun Chang; Jin Hyoung Kang; Sook Hee Hong; Myung Sin Kim; Yeon Sil Kim Journal: Tumour Biol Date: 2015-08-04
Authors: Jamal Zaini; Elisna Syahruddin; Muhammad Yunus; Sita Laksmi Andarini; Achmad Hudoyo; Najmiatul Masykura; Refniwita Yasril; Asep Ridwanuloh; Heriawaty Hidajat; Fariz Nurwidya; Sony Suharsono; Ahmad R H Utomo Journal: Cancer Rep (Hoboken) Date: 2019-02-03